Inotersen sodium - Generic Drug Details

What are the generic sources for inotersen sodium and what is the scope of freedom to operate?

Inotersen sodium is the generic ingredient in one branded drug marketed by Akcea Theraps and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Inotersen sodium has thirty-five patent family members in twenty-five countries.

Summary for inotersen sodium

International Patents:	35
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	inotersen sodium at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for inotersen sodium

Constraining patent/regulatory exclusivity:

8,697,860

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for inotersen sodium

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

US Patents and Regulatory Information for inotersen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	9,061,044			Y
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	8,697,860		Y
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018		DISCN	Yes	No	9,399,774

Expired US Patents for inotersen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	8,101,743
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	7,015,315
Akcea Theraps	TEGSEDI	inotersen sodium	SOLUTION;SUBCUTANEOUS	211172-001	Oct 5, 2018	7,101,993

International Patents for inotersen sodium

Country	Patent Number	Title	Estimated Expiration
Portugal	2563920
Cyprus	D2019001
Canada	2994063
Denmark	2563920
Poland	2563920
Spain	2625689

Supplementary Protection Certificates for inotersen sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2563920	C201930001	Spain		PRODUCT NAME: INOTERSEN Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN PARTICULAR LA SAL SODICA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1296; DATE OF AUTHORISATION: 20180706; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1296; DATE OF FIRST AUTHORISATION IN EEA: 20180706
2563920	2019C/001	Belgium		PRODUCT NAME: UN OLIGONUCLEOTIDE MODIFIE AYANT UNE SEQUENCE CONSTITUEE DE NUCLEOSIDES RELIES TELLE QUE DEFINIE AU BREVET EP-B1-2563920, ET SPECIFIQUEMENT L'INOTERSEN; ET SES DERIVES, TELS QUE SES SELS, EN CE COMPRIS LES SELS SODIQUES; AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710
2563920	354 1-2019	Slovakia		PRODUCT NAME: INOTERSEN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/18/1296 20180710
2563920	C20190002 00303	Estonia		PRODUCT NAME: INOTERSEEN;REG NO/DATE: EU/1/18/1296 10.07.2018
2563920	132019000000004	Italy		PRODUCT NAME: INOTERSEN(TEGSEDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1296, 20180710
2563920	LUC00096	Luxembourg		PRODUCT NAME: INOTERSEN AND SALTS THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1296 20180710

Inotersen sodium Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Inotersen Sodium?

Inotersen sodium, an experimental drug primarily aimed at treating neurodegenerative conditions, faces a complex market landscape. The drug is not yet approved for mainstream use, preventing revenue generation. Its market potential depends largely on clinical trial outcomes, regulatory decisions, and competitive positioning within neurology therapeutics.

Key drivers influencing market dynamics include the prevalence of target conditions—such to as cognitive decline and neurodegenerative diseases—and the pipeline competition. Conditions like Alzheimer's disease and vascular dementia increasingly drive demand, with the global Alzheimer’s market projected to reach $16.3 billion by 2027 (Fortune Business Insights).

Barriers include regulatory hurdles, access to reimbursement, and the drug’s clinical efficacy profile. Given the competitive environment with drugs like donepezil and memantine, Inotersen sodium’s therapeutic advantages will influence its market penetration.

What Is the Current Clinical Development Stage and Regulatory Status?

Inotersen sodium is in Phase 2 clinical trials as of 2023. The trials assess safety, tolerability, pharmacokinetics, and initial efficacy in patients with cognitive impairment. No approval or regulatory submissions are filed yet.

Potential timeline considerations:

• Phase 3 trials could need 2-3 years for completion.
• Regulatory approval might follow 1-2 years post-Phase 3.

Approval depends on demonstrating statistical significance in primary endpoints, with regulatory agencies such as the FDA and EMA requiring large-scale, randomized trials showing clear benefits over existing treatments.

How Does the Competitive Landscape Impact Its Market Prospects?

Inotersen sodium competing against established drugs like:

• Donepezil (marketed since 1996).
• Memantine (approved since 2003).
• Rivastigmine and others.

Emerging therapies, including monoclonal antibodies targeting amyloid beta (e.g., Aducanumab), create additional competition. The success of Inotersen sodium depends on differentiation, such as improved efficacy, safety profile, or novel mechanisms.

Market share faces constraints from these incumbents, with combined revenues of more than $10 billion annually. Any new approval must demonstrate significant benefits or unmet needs to capture share.

What Are the Financial Trajectories and Investment Considerations?

No revenue exists for Inotersen sodium at present. R&D costs for neurodegenerative drugs average between $1 billion and $2 billion per molecule, considering failure rates and long development timelines. The investment trajectory involves:

• High upfront costs until clinical success.
• Potential for licensing or partnership deals during later phases to offset costs.
• Diminished immediate financial risk but significant long-term uncertainty.

If approved, revenues depend on pricing, reimbursement, and market uptake. Neurodegenerative drugs often attain premium pricing, with annual costs reaching $5,000 to $15,000 per patient.

Projected market entry could see peaks of $500 million in annual sales if the drug demonstrates substantial clinical benefits and secures reimbursement. Failure at trial or regulatory hurdles could result in total loss of R&D investment.

What Is the Regulatory and Policy Environment?

Regulatory pathways for neurodegenerative drugs include accelerated approval programs if biomarkers or surrogate endpoints are validated. The FDA has pushed avenues for drugs demonstrating potential benefits in early-stage trials for Alzheimer's and related disorders.

Policy incentives include grants from agencies like NIH and BARDA, along with orphan drug designations if applicable. Policies vary across regions, influencing market access and reimbursement prospects.

What Are the Key Risk Factors?

• Clinical efficacy: Failure to show statistically significant benefit.
• Regulatory approval: Stringent requirements for confirming benefits.
• Competitive landscape: Entry of superior pipeline drugs.
• Commercialization: Reimbursement landscapes and pricing pressures.
• Scientific risks: Uncertainty around mechanism of action effectiveness.

Key Takeaways

• Inotersen sodium remains in early clinical development, with no current revenues.
• It targets large, growing markets with high unmet needs.
• Competitive threats from established drugs and emerging therapies are significant.
• Long development timelines and high R&D costs impose financial risk.
• Success depends on clinical trial outcomes, regulatory approval, and market access strategies.

FAQs

1. What is the primary therapeutic target of Inotersen sodium?
Inotersen sodium aims to improve cognitive function and slow neurodegeneration, likely targeting pathways involved in neuronal survival and synaptic plasticity.

2. When could Inotersen sodium realistically reach the market?
If Phase 2 trials show promising results and Phase 3 begins immediately, approval could occur within 4-6 years, around 2027-2029.

3. How does market competition influence Inotersen sodium’s potential revenue?
Existing drugs dominate the market, with established safety profiles and reimbursement. Inotersen sodium must offer clear advantages to gain significant market share.

4. What are the main financial risks for investors in Inotersen sodium?
Major risks include failure in clinical trials, regulatory rejection, or inability to differentiate from existing therapies. Upfront R&D costs are high, with no guaranteed return.

5. What policy factors could accelerate or delay approval?
Regulatory agencies’ acceptance of surrogate endpoints and accelerated approval pathways could reduce development time, while delay in clinical success or regulatory scrutiny could extend timelines.

---

References

1. Fortune Business Insights. Alzheimer’s disease market size forecast, 2027.
2. FDA. Guidance for Industry: Accelerated Approval Program, 2014.
3. Reuters. Neurodegenerative drug development profiles, 2022.
4. IQVIA. Global neurodegenerative therapies market analysis, 2023.
5. ClinicalTrials.gov. Inotersen sodium trial records, 2023.